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potheses have been proposed; these include "allosteric" effects on enzymes (1), redirection of lymphocyte traffic (2) , direct inhibition of various phospholipases (3), induction of such proteins as lipocortin (4), inhibition of the transcription of various cytokines and metalloproteases (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , and our own earlier suggestion that glucocorticoids stabilize lysosomal and other cellular membranes (15, 16) . However, none of these hypotheses is sufficient to account for the well-known pharmacologic effects of glucocorticoids in humans: leukocytosis (17) , inhibition of leukocyte recruitment to inflamed areas (18, 19) , retention of lymphocytes in the lymphatic circulation with shrinkage ofperipheral lymph nodes, and the promotion of microbial infection (2) .
Recent studies have suggested that endothelial cells can direct the traffic of leukocytes into inflamed and infected areas (heterotypic adhesion) via the regulated expression of surface adhesive molecules [e.g., GMP140, endothelialleukocyte adhesion molecule 1 (ELAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule (VCAM) (20) (21) (22) (23) ]. In a complementary fashion, leukocytes also express proteins [CD11a-c/CD18, L-selectin, or lectin/epidermal growth factor cell adhesion molecule 1 (LECAM-1)] on their surface that mediate their specific localization to sites of inflammation (24, 25) . Agents Medium 199, RPMI 1640, and fetal bovine serum were obtained from GIBCO. Ficoll/Hypaque was purchased from Nyegaard (Oslo). All other salts and reagents were of the highest quality that could be obtained.
Monoclonal Antibodies. In these studies the monoclonal antibodies used included antibodies directed against ICAM-1 (84H10, AMAC, Westbrook, ME), ELAM-1 (BMA 4D10, Accurate Chemicals, Westbury, NY, and H18/7, a generous gift of Michael Bevilacqua, San Diego), MOPC21, and UPC10, nonbinding isotype controls. Fluorescein-labeled anti-IgG, goat anti-mouse fluorescein isothiocyanate (GAM-FITC) was obtained from Coulter Immunology. Endothelial cells were also stained with rhodamine-labeled Ulex europaeus agglutinin I (Vector Laboratories); all monoclonal antibody studies were performed in ice-cold phosphate-buffered saline (PBS) with 0.02% sodium azide and 0.025% bovine serum albumin.
Culture of Endothelial Cells. Human umbilical vein endothelial cells (HUVECs) were cultured as described (26) . All experiments were performed on endothelial cells in their third passage.
Incubation of Endothelial Cells with Pharmacologic Agents. Endothelial cells were stimulated by incubation with LPS (1 Ag/ml) in a medium consisting of RPMI 1640/10% fetal bovine serum for 4 hr at 37°C in a 5% CO2 atmosphere with or without other agents as indicated. The monolayers were then washed three times.
PMN Adherence to Endothelial Monolayers (Heterotypic Adherence). PMNs (150,000 per well), isolated from whole blood as described (27) , suspended in RPMI 1640 medium, were added to monolayers of endothelial cells and incubated for 10 min at 37°C in a 5% CO2 atmosphere and adherence was determined as described (28) . Pretreatment of unstimulated HUVECs with each of the agents used did not affect basal PMN adherence (data not shown). The highest concentration of diluent used (ethanol, 0.1%) also had no effect on PMN adherence to LPS-stimulated endothelium.
In some experiments PMNs were labeled with "'tIn and after incubation oflabeled PMNs with endothelium for 10 min at 37°C adherence was determined by a previously described method (29) and expressed as % adherence.
Expression of ELAM-1 and ICAM-1. After incubation for 4 hr with various stimuli and agents the HUVECs were removed from wells by exposure to EDTA (0.01%, wt/vol) in PBS for 10 Dexamethasone (IC50 < 1 nM) inhibited the LPS-stimulated expression of ELAM-1 and ICAM-1 (P < 0.00001 and P < 0.00001, respectively, Fig. 3 ) without altering basal expression of these molecules (data not shown). Dexamethasone did not alter binding of rhodamine-labeled Ulex europaeus agglutinin I to the endothelial cell surface (Fig. 2) . Similarly, none of the compounds studied affected the nonspecific binding of antibodies MOPC21, UPC10 (isotype controls), or FITC antimouse IgG (data not shown). As expected, RU-486 completely reversed the effect of dexamethasone on the LPS-stimulated expression ofICAM-1 and ELAM-1 (P < 0.004, Figs. 2 and 4) . Although RU-486 appeared to diminish LPS-stimulated upregulation ofICAM-1 (Fig. 4) , the difference observed was not statistically significant. Similarly, cortisol, but neither tetrahydrocortisol nor sodium salicylate, inhibited expression of ICAM-1 and ELAM-1 (P < 0.003, Fig. 5 ). None of the agents studied affected binding of Ulex europaeus agglutinin I to HUVECs (Fig. 2) .
Glucocorticoids Prevent Accumulation of Message for ELAM-1 in Response to LPS and IL-la But Not in Response to TNF. To further define the mechanism by which glucocorticoids inhibit up-regulation of adhesive molecules, we studied the effect of dexamethasone (0.1 pM) on the level of mRNA for ELAM-1 in HUVECs. Treatment of HUVECs with LPS, IL-la (20 units/ml), and TNF (50 units/ml) stimulated a marked increase in detectable message for ELAM-1 in HUVECs (Fig. 5) . Dexamethasone (0.1 uM) did not affect basal levels of mRNA for ELAM-1 but markedly inhibited the LPSand IL-la-stimulated increase in message. In contrast, dexamethasone did not affect the TNF-stimulated increment in detectable ELAM-1 message, an observation that suggests that glucocorticoids do not directly affect stability of message for ELAM-1. Although these findings need to be fortified by further studies of the effects ofglucocorticoids on the stability of ELAM-1 message and the rate of transcription of ELAM-1 by stimulated endothelium, the results suggest that glucocorticoids act at the transcriptional level.
Dexamethasone Does Not Reverse the Effect of TNF-a on Endothelial Adhesiveness for PMNs. Since dexamethasone did not affect the level of message for ELAM-1 in TNF-astimulated HUVECs, we sought to determine whether this was reflected in the adhesiveness of TNF-a-treated endothelium for PMNs. As previously reported, TNF-a (50 units/ml) rendered the endothelium more adhesive to PMNs (23% + 1% adherence vs. 9% ± 2% adherence, n = 4, P < 0.01) and dexamethasone did not diminish the increased adhesiveness of TNF-stimulated endothelium for PMNs (21% ± 1% adherence, n = 4). DISCUSSION We show here that one important mechanism by which glucocorticoids may affect the inflammatory response is modulation of the capacity of the endothelium to respond to an inflammatory stimulus. Glucocorticoids, acting at their cytoplasmic receptors, diminish the LPS-stimulated increase in endothelial adhesiveness for resting PMNs and diminish transcription and expression of pro-inflammatory adhesive molecules on the surface of the endothelium. Since recent studies have increasingly pointed to the central role of the endothelium in directing the traffic of leukocytes into inflamed areas, our observations bear directly on the mechanism for the antiinflammatory effects of glucocorticoids. Moreover, our results help to explain the dramatic leukocytosis observed in patients taking therapeutic doses of corticosteroids [concentrations similar to those studied here (17) ].
RU-486 stabilizes the association of steroid receptors with heat shock protein 90 in the presence ofligand, which prevents translocation of glucocorticoid receptors to the nucleus and thereby blocks transcription of genes containing glucocorticoid-responsive elements (33, (35) (36) (37) (38) (39) (40) . Our demonstration that RU-486 reverses the effects ofdexamethasone on the adhesive qualities of HUVECs and the expression of adhesive molecules on their surface is therefore most consistent with the hypothesis that the effects of steroids on the endothelium are mediated through glucocorticoid receptors. Further confirmation is provided by the observation that cortisol, but not its inactive metabolite tetrahydrocortisol, inhibits endothelial cell responses to LPS. The absence of a glucocorticoid-responsive element in the gene for ELAM We were surprised to observe that dexamethasone did not inhibit accumulation of mRNA for ELAM-1 induced by TNF-a. In parallel studies Ghezzi and Sipe (43) In addition to these direct receptor-mediated effects of glucocorticoids on the capacity of HUVECs to localize the inflammatory response, glucocorticoids also inhibit the ligandinduced release of cytokines (IL-1, IL-3, and TNF-a) by endothelial and other inflammatory cells (5) (6) (7) (8) (9) (10) (11) (12) . These findings suggest the general hypothesis that corticosteroids act as antiinflammatory agents by diminishing, directly and indirectly, the ability of HUVECs to direct leukocyte traffic into inflamed or infected tissue. Our data also provide a reasonable explanation for the opposing effects of endotoxin and glucocorticoids in infection and immunity (15, 16) .
